Q32 Bio Inc.

Q32 Bio Inc. reported a profitable fiscal year 2025 with net income of $29.8 million, driven primarily by collaboration arrangement revenue of $53.7 million and a significant gain on sale of asset of $11.7 million. The company generated income from operations of $16.9 million despite total operating expenses of $36.8 million, which included research and development costs of $19.2 million and general and administrative expenses of $17.7 million. The balance sheet shows total assets of $61.8 million, with cash and cash equivalents of $48.3 million and total stockholders' equity of $42.0 million. However, cash flow from operations was negative at -$33.5 million, primarily due to non-cash revenue recognition and working capital changes, resulting in a net decrease in cash of $29.7 million for the year. The company's basic and diluted earnings per share were both $2.00.

Key Takeaways